At a Glance
  • Status: Completed Consortium
  • Year Launched: 2004
  • Initiating Organization: Breast International Group
  • Initiator Type: Industry
  • Disease focus:
  • Location: Europe


TRANSBIG comprises 28 world-class institutions in 11 countries. Each participating organization brings with it expertise that ranges from specialization in cutting-edge biomedical technologies and cancer treatment programs to representing patient groups and supporting cancer societies. Among its many strengths is the fact that TRANSBIG is linked to an already existing network of groups from around the world that conduct clinical breast cancer trials together – the Breast International Group (BIG).


The main objectives of TRANSBIG were:

to accelerate the way laboratory discoveries for breast cancer “translate” into treatments for patients (translational research)

to advance personalized treatment for breast cancer patients

to strengthen and facilitate collaboration in translational breast cancer research in Europe and internationally

Consortium History

2007 - MindAct Trial

TRANSBIG/MindAct Biobank

TRANSBIG traineeship programme

Structure & Governance

The consortium is governed by Breast International Group.


Funding from the European Commission under Framework Programme VI (FP6)


Click here for a description of consortium accomplishments

Points of Contact

Breast International Group (BIG)-aisbl
Blvd de Waterloo 121
B-1000 Brussels | Belgium
VAT BE 0468 176 240

Sponsors & Partners


Last Updated: 06/21/2017

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.